Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Systemic Lupus Erythematosus
In brief
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
Key facts
- Study ID
- NCT06161116
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 149
- Starts
- 2023-12-27
- Expected to finish
- 2025-07-30
- Last updated by the study team
- 2025-08-06
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Has a diagnosis of systemic lupus erythematosus (SLE) ≥6 months prior to Screening.
- Is taking at least 1 background therapy (1 immunosuppressant or dapsone and/or 1 antimalarial and/or oral corticosteroids) for SLE.
- Has + antinuclear antibody (+ANA) (titer ≥1:80) or positive anti-double-strand deoxyribonucleic acid (dsDNA) antibody or positive anti-Sm antibody, or positive anti-SSA/Ro antibody.
- Has the presence of at least one of the following manifestations of SLE: Active lupus rash with CLASI-A erythema and scale/hypertrophy combined score >2, or >2 tender and swollen joints in wrists, metacarpophalangeals (MCPs), or proximal interphalangeals (PIPs).
- Has a hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score of ≥6 and clinical hybrid SLEDAI score of ≥4.
You may not qualify if…
- Has a concurrent clinically significant disease or clinically relevant laboratory abnormalities, or a history of any illness or medical condition that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
- Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening.
- Has a severe chronic pulmonary disease requiring oxygen therapy.
- Has a transplanted organ which requires continued immunosuppression.
- Has a known systemic hypersensitivity to IL-2, or modified IL-2 including MK-6194, or its inactive ingredients.
- Has a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
- Has drug-induced cutaneous lupus erythematosus (CLE) and/or drug-induced SLE in the setting of continued treatment with a causative agent.
- Has active or unstable neuropsychiatric lupus including but not limited to the following: seizure, new or worsening impaired level of consciousness, psychosis, delirium or confused state, aseptic meningitis, cranial neuropathy, cerebrovascular accident, ascending or transverse myelitis, chorea, cerebellar ataxia, mononeuritis multiplex, or demyelinating syndromes.
- Has a diagnosis of Antiphospholipid Syndrome with history of vascular thrombosis, catastrophic APS, or pregnancy morbidity within 6 months prior to Screening.
- Has a history of any malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.
- Has an active or clinically significant infection requiring hospitalization or treatment with anti-infectives.
- Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.
- Has confirmed or suspected COVID-19 infection.
- Has had major surgery within 3 months prior to Screening or has a major surgery planned during the study.
- Is taking more than 1 immunosuppressant.
- Is taking more than 1 oral NSAID (excluding low-dose aspirin [<350 mg/day]) or is taking daily oral nonsteroidal anti-inflammatory drug (NSAID) at greater than the maximum recommended dosage.
- Is currently on any chronic systemic (oral or IV) anti-infective therapy for chronic active infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).
Where it is running
- UCSD - Altman Clinical and Translational Research Institute (ACTRI)-Center for Innovative Therapy ( Site 0110) — La Jolla, California, United States
- Arthritis & Osteoporosis Medical Center - La Palma ( Site 0108) — La Palma, California, United States
- Medvin Clinical Research - Tujunga ( Site 0127) — Tujunga, California, United States
- Denver Arthritis Clinic ( Site 0102) — Denver, Colorado, United States
- Clinical Research of West Florida, Inc. (Clearwater) ( Site 0111) — Clearwater, Florida, United States
- IRIS Research and Development, LLC-Research ( Site 0117) — Plantation, Florida, United States
- Clinical Research of West Florida, Inc ( Site 0124) — Tampa, Florida, United States
- Morehouse School of Medicine ( Site 0146) — Atlanta, Georgia, United States
- Accurate Clinical Research, Inc ( Site 0135) — Lake Charles, Louisiana, United States
- AA Medical Research Center ( Site 0136) — Grand Blanc, Michigan, United States
- Javara - Tryon Medical Partners ( Site 0121) — Charlotte, North Carolina, United States
- DJL Clinical Research, PLLC ( Site 0103) — Charlotte, North Carolina, United States
- University of Oklahoma Health Science Center ( Site 0130) — Oklahoma City, Oklahoma, United States
- Shelby Research, LLC ( Site 0142) — Memphis, Tennessee, United States
- Accurate Clinical Management, LLC. ( Site 0134) — Baytown, Texas, United States
- Epic Medical Research ( Site 0113) — DeSoto, Texas, United States
- Accurate Clinical Research, Inc. ( Site 0133) — Houston, Texas, United States
- SouthWest Rheumatology Research, LLC ( Site 0115) — Mesquite, Texas, United States
- Centro de Investigaciones Médicas Mar del Plata ( Site 0210) — Mar del Plata, Buenos Aires, Argentina
- Sanatorio Parque ( Site 0205) — Rosario, Santa Fe Province, Argentina
- Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0206) — Santa Fe, Santa Fe Province, Argentina
- Centro de Investigaciones Médicas Tucuman ( Site 0203) — SAN M. de Tucuman, Tucumán Province, Argentina
- Instituto de Reumatología ( Site 0201) — Mendoza, Argentina
- IPC - MT Instituto de Pesquisas Clínicas do Mato Grosso ( Site 0313) — Cuiabá, Mato Grosso, Brazil
- Medvin Clinical Research - Metyas ( Site 0128) — Covina, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.